Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris starting November 26, 2025, pending the announcement of its capital increase results [1] - Trading is expected to resume on November 27, 2025, at market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment, with a portfolio that includes several viral vector-based immunotherapies in clinical development [2] - The lead candidate, TG4050, is the first individualized treatment from the myvac® platform, showing clinical proof of concept in patients with head and neck cancer [2] - Other candidates in development include BT-001, an oncolytic virus based on the patented invir.IO® platform [2] Technology and Innovation - The myvac® platform integrates tumor mutations identified through artificial intelligence into a viral vector, marking a step into precision medicine [3] - The invir.IO® platform allows for the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris pending the publication of results from its capital increase [1] - Trading is expected to resume on November 27, 2025, at the market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment [2] - The company's lead candidate, TG4050, is an individualized treatment that has shown clinical proof of concept in patients with head and neck cancer [2] - Transgene is also developing other candidates, including BT-001, which is based on a patented oncolytic virus [2] Technology Platforms - The myvac® platform allows for patient-specific immunotherapy by integrating tumor mutations identified through artificial intelligence [3] - The invir.IO® platform enables the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Points - Transgene is launching a fundraising initiative to raise approximately €105 million through the issuance of new shares, targeting specialized investors via private placement and retail investors through the PrimaryBid platform [2][6] - The company aims to accelerate the development of its myvac® platform, particularly the individualized cancer vaccine TG4050, which has shown promising results in patients with operable head and neck cancer [4][5] - The funds raised will extend the company's financial visibility until early 2028, allowing for ongoing clinical trials and preparation for potential pivotal trials [6][8] Fundraising Details - The fundraising consists of a private placement for institutional investors and a public offering for retail investors, with TSGH committing to invest at least €70 million [11][14] - The private placement and PrimaryBid offering will close on November 26, 2025, with trading of Transgene shares suspended on that day [6][32] - The net proceeds from the fundraising will be allocated primarily to the myvac® program (approximately 70%), followed by R&D costs (approximately 20%), and general operational expenses [7][8] Financial Position - Prior to the fundraising, Transgene had €11.1 million in cash and a drawing capacity of €8.7 million on its Current Account Advance [9] - Following the fundraising, the company expects to meet its working capital requirements until early 2028, significantly improving its financial stability [10][8] - The Reserved Capital Increase of approximately €39.4 million will be executed at the same price as the private placement, converting debt into equity and strengthening the company's balance sheet [34][36] Expected Milestones - Key milestones for the myvac® platform include follow-up data from ongoing trials in head and neck cancers, with significant data expected in 2026 and 2027 [13] - The company plans to launch a Phase 1 trial in a new indication once financing conditions are met, with preparations for late-stage trials expected to conclude by the end of 2027 [12][13] Shareholder Structure - As of the date of the press release, TSGH holds 68.87% of the company's share capital, and after the fundraising, its stake is expected to decrease slightly to 68.06% [28][29] - The fundraising will result in dilution for existing shareholders, with the shareholding percentage for a shareholder holding 1% of the capital before the fundraising expected to drop to approximately 0.63% post-issuance [27]

Core Points - Transgene has appointed Emmanuelle Quilès as an independent Director to its Board of Directors, succeeding Philippe Archinard, who is retiring [1][3] - Emmanuelle Quilès brings over 25 years of experience in strategic leadership roles within the global pharmaceutical industry, previously serving as Worldwide Vice President at Janssen Global Commercial Strategy Organization [2][5] - The appointment is effective from July 9, 2025, and Quilès will serve the remainder of Archinard's term until the 2026 Annual Shareholders' Meeting [3] Company Overview - Transgene is a biotechnology company focused on designing and developing virus-based immunotherapies for cancer treatment, with a portfolio that includes TG4050, TG4001, BT-001, and TG6050 [8] - The company utilizes its myvac® platform for individualized therapeutic vaccines and the Invir.IO® platform for multifunctional oncolytic viruses [9][10] - Transgene's clinical-stage programs are aimed at providing targeted immunotherapies, with a focus on precision medicine [8][9]

Core Insights - Transgene will present two-year disease-free survival data from the Phase I part of the TG4050 trial at ASCO 2025 [1][3] - TG4050 is an individualized neoantigen therapeutic cancer vaccine developed using Transgene's myvac® platform and NEC's AI capabilities [2][10] - The Phase I/II trial is focused on HPV-negative head and neck cancers, with the Phase II part currently enrolling patients internationally [3][12] Company Overview - Transgene is a biotechnology company specializing in virus-based immunotherapies for cancer treatment [5][7] - The company’s lead asset, TG4050, is the first individualized therapeutic vaccine based on the myvac® platform [5][10] - Transgene is also developing other viral vector-based immunotherapies, including TG4001 for HPV-positive cancers [7] Clinical Trial Details - The Phase I/II trial evaluates TG4050 as a single agent in the adjuvant treatment of HPV-negative head and neck cancers [3][12] - The trial includes a randomized study design with 32 evaluable patients in the Phase I part [12] - The Phase II extension is currently enrolling patients, indicating ongoing development and potential for future data [3][12] Presentation and Recognition - The rapid oral presentation at ASCO will take place on June 1, 2025, highlighting the clinical data and collaborative efforts in the trial [1][3] - Transgene's findings on TG4050 were selected for presentation among numerous high-quality submissions, reflecting the significance of their work [3]

Core Points - The Combined Ordinary and Extraordinary General Meeting of Transgene's shareholders took place on May 15, 2025, where various resolutions were voted on and approved [1][2] - The meeting resulted in the renewal of the terms of office for several Board Members, maintaining a diverse and independent Board composition [3][4] - A share capital reduction was approved, decreasing the par value of shares from €0.50 to €0.30, along with the delegation of authority for a potential reverse stock split [5] Company Overview - Transgene is a biotechnology company focused on developing targeted immunotherapies for cancer treatment, with a portfolio that includes viral vector-based immunotherapeutics [7] - The lead asset, TG4050, is an individualized therapeutic vaccine aimed at head and neck cancers, showcasing the company's innovative approach to precision medicine [8] - Transgene utilizes its proprietary Invir.IO® platform to engineer multifunctional oncolytic viruses, enhancing its capabilities in viral vector technology [9]